Table 1. Baseline Characteristics of Aspirin in Reducing Events in the Elderly Trial Participants Who Remained Free of Mortality Through the Second Annual Visit.
| Characteristic | Participants, No. (%) | P value | |||||
|---|---|---|---|---|---|---|---|
| All | Within 5% weight change or stable weight | Increase in weight | Decrease in weight | ||||
| 5%-10% | >10% | 5%-10% | >10% | ||||
| No. (%) | 16 523 (100.0) | 12 370 (74.9) | 1299 (7.9) | 314 (1.9) | 1953 (11.8) | 587 (3.6) | NA |
| Age, mean (SD), y | 75.0 (4.3) | 75.0 (4.4) | 74.6 (4.1) | 74.7 (4.5) | 75.5 (4.8) | 75.6 (4.8) | <.001 |
| Sex | |||||||
| Male | 7330 (44.4) | 5750 (46.5) | 525 (40.4) | 107 (34.1) | 765 (39.2) | 183 (31.2) | <.001 |
| Female | 9193 (55.6) | 6620 (53.5) | 774 (59.6) | 207 (65.9) | 1188 (60.8) | 404 (68.8) | |
| Country | |||||||
| Australia | 14 632 (88.6) | 10 984 (88.8) | 1170 (90.1) | 277 (88.2) | 1711 (87.6) | 490 (83.5) | <.001 |
| US | 1891 (11.4) | 1386 (11.2) | 129 (9.9) | 37 (11.8) | 242 (12.4) | 97 (16.5) | |
| Low physical activity | 1139 (6.9) | 806 (6.5) | 88 (6.8) | 23 (7.3) | 167 (8.6) | 55 (9.4) | .002 |
| Weight, mean (SD), kg | 77.1 (14.8) | 77.2 (14.6) | 75.2 (14.5) | 71.8 (14.2) | 77.3 (15.2) | 80.1 (16.9) | <.001 |
| Waist circumference, mean (SD), cm | 97.1 (12.7) | 97.1 (12.5) | 96.4 (13.2) | 95.1 (13.0) | 97.5 (13.2) | 98.9 (14.4) | <.001 |
| Current or former smoking | 7276 (44.0) | 5387 (43.5) | 594 (45.7) | 151 (48.1) | 863 (44.2) | 281 (47.9) | .08 |
| Current alcohol use | 12 806 (77.5) | 9717 (78.6) | 992 (76.4) | 231 (73.6) | 1453 (74.4) | 413 (70.4) | <.001 |
| Educational level, y | |||||||
| <12 | 9371 (56.7) | 6980 (56.4) | 795 (61.2) | 194 (61.8) | 1083 (55.5) | 319 (54.3) | .002 |
| ≥12 | 7152 (43.3) | 5390 (43.6) | 504 (38.8) | 120 (38.2) | 870 (44.5) | 268 (45.7) | |
| Hypertension | 12 222 (74.0) | 9104 (73.6) | 956 (73.6) | 225 (71.7) | 1492 (76.4) | 445 (75.8) | .07 |
| Dyslipidemia | 10 789 (65.3) | 8040 (65.0) | 846 (65.1) | 207 (65.9) | 1321 (67.6) | 375 (63.9) | .21 |
| Chronic kidney disease | 2878/16 113 (17.9) | 2099/12 067 (17.4) | 214/1265 (16.9) | 59/305 (19.3) | 384/1905 (20.2) | 122/571 (21.4) | .005 |
| Diabetes | 1721 (10.4) | 1236 (10.0) | 135 (10.4) | 41 (13.1) | 245 (12.5) | 64 (10.9) | .006 |
| Prefrail or frail | 6503 (39.4) | 4708 (38.1) | 509 (39.2) | 145 (46.2) | 861 (44.1) | 280 (47.7) | <.001 |
| ≥1 Interim hospitalization | 3403 (20.6) | 2356 (19.0) | 276 (21.2) | 80 (25.5) | 476 (24.4) | 215 (36.6) | <.001 |
| Taking trial medication (100 mg of aspirin) | 8199 (49.6) | 6125 (49.5) | 651 (50.1) | 163 (51.9) | 961 (49.2) | 299 (50.9) | .85 |
| Outcomes | |||||||
| All-cause mortality | 1256 (7.6) | 850 (6.9) | 87 (6.7) | 30 (9.6) | 183 (9.4) | 106 (18.1) | <.001 |
| Cancer mortality | 563/15 830 (3.6) | 385/11 905 (3.2) | 39/1251 (3.1) | 11/295 (3.7) | 79/1849 (4.3) | 49/530 (9.2) | <.001 |
| Cardiovascular disease mortality | 316/15 583 (2.0) | 215/11 735 (1.8) | 25/1237 (2.0) | 6/290 (2.1) | 47/1817 (2.6) | 23/504 (4.6) | <.001 |
| Noncancer non-CVD mortality | 377/15 644 (2.4) | 250/11 770 (2.1) | 23/1235 (1.9) | 13/297 (4.4) | 57/1827 (3.1) | 34/515 (6.6) | <.001 |
Abbreviations: CVD, cardiovascular disease; NA, not applicable.